Swedish Orphan Biovitrum AB (publ) Just Recorded A 30% EPS Beat: Here's What Analysts Are Forecasting Next

As you might know, Swedish Orphan Biovitrum AB (publ) (STO:SOBI) just kicked off its latest quarterly results with some very strong numbers. It was overall a positive result, with revenues beating expectations by 5.5% to hit kr6.5b. Swedish Orphan Biovitrum also reported a statutory profit of kr2.52, which was an impressive 30% above what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

We check all companies for important risks. See what we found for Swedish Orphan Biovitrum in our free report.

Following the latest results, Swedish Orphan Biovitrum's eleven analysts are now forecasting revenues of kr28.7b in 2025. This would be a meaningful 9.3% improvement in revenue compared to the last 12 months. Per-share earnings are expected to ascend 18% to kr13.56. Before this earnings report, the analysts had been forecasting revenues of kr28.0b and earnings per share (EPS) of kr13.51 in 2025. There doesn't appear to have been a major change in sentiment following the results, other than the small lift in revenue estimates.

Check out our latest analysis for Swedish Orphan Biovitrum

It may not be a surprise to see thatthe analysts have reconfirmed their price target of kr354, implying that the uplift in revenue is not expected to greatly contribute to Swedish Orphan Biovitrum's valuation in the near term. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Swedish Orphan Biovitrum analyst has a price target of kr385 per share, while the most pessimistic values it at kr285. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 13% growth on an annualised basis. That is in line with its 13% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 17% annually. So it's pretty clear that Swedish Orphan Biovitrum is expected to grow slower than similar companies in the same industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also upgraded their revenue estimates for next year, even though it is expected to grow slower than the wider industry. The consensus price target held steady at kr354, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Swedish Orphan Biovitrum going out to 2027, and you can see them free on our platform here..

You can also view our analysis of Swedish Orphan Biovitrum's balance sheet, and whether we think Swedish Orphan Biovitrum is carrying too much debt, for free on our platform here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.